CMC Medical Staff Transfusion Guidelines. Table of Contents edition INTRODUCTION:
|
|
- Jessie Howard
- 5 years ago
- Views:
Transcription
1 CMC Medical Staff Transfusion Guidelines 2014 edition INTRODUCTION: The CMC Blood Component and Transfusion Guidelines have been approved by the multidisciplinary Transfusion Committee. These are based on current evidence and recently published expert guidelines. These transfusion guidelines are not intended to be proscriptive rules, but they are applicable to many common clinical circumstances in which transfusion is considered. Table of Contents BLOOD PRODUCTS... 2 I. RED BLOOD CELLS (RBC)... 2 II. PLATELETS (PLT)... 3 III. PLASMA (FFP)... 5 IV. CRYOPRECIPITATE (CRYO)... 6 V. GRANULOCYTES... 7 NEONATAL TRANSFUSION GUIDELINES - INFANTS < 4 MONTHS... 8 I. RED BLOOD CELLS (RBC) - INFANTS < 4 MONTHS... 8 II. PLATELETS (PLT) - INFANTS < 4 MONTHS... 8 III. PLASMA (FFP) AND CRYOPRECIPITATE (CRYO) - INFANTS < 4 MONTHS... 8 SPECIAL BLOOD PRODUCT/COMPONENT MODIFICATIONS... 9 I. IRRADIATION OF CELLULAR BLOOD COMPONENTS... 9 II. CYTOMEGALOVIRUS (CMV)-NEGATIVE COMPONENTS III. SICKLE CELL-NEGATIVE RED BLOOD CELLS (RBC) IV. SPECIAL PLATELET ORDERS FOR REFRACTORY PATIENTS (CROSSMATCHED/HLA MATCHED) V. PRE-OPERATIVE AUTOLOGOUS BLOOD DONATION (PAD) BLOOD PRODUCTS--SPECIAL TRANSFUSION ORDER GUIDANCE I. BLOOD WARMING II. PREMEDICATION TO PREVENT TRANSFUSION REACTIONS Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 1
2 BLOOD PRODUCTS I. RED BLOOD CELLS (RBC) How Supplied: All Red Blood Cell products issued at CMC facilities are leukocyte-reduced. Volume of one unit is ml. Cost: CMC acquisition cost per RBC unit is $245. Cost inclusive of staff time and infusion supplies is estimated at $500. Utilization Review Guidelines: Red cell transfusion may be appropriate to improve oxygen carrying capacity. Documentation of the indication(s) for transfusion and special circumstances for transfusions ordered outside these guidelines is required. Indications: 1) Acute Blood Loss: Maintain circulating blood volume with fluid resuscitation. If timely hemoglobin and hematocrit testing is available, consider transfusion if hemoglobin is less than 7 g/dl in otherwise healthy patients; less than 8g/dL in elderly patients and those with known ischemic cardiac or respiratory disease. If decision is based on blood loss: a) 15-30% loss of blood volume: RBC transfusion likely not required b) 30-40% loss of blood volume: RBC transfusion probably required c) Greater than 40% loss of blood volume: RBC transfusion almost certainly required. 2) Massive transfusion protocol (MTP) includes 5 RBC, 5 plasma, and 1 pheresis platelet in each MTP pack. 3) Anemia in the absence of acute blood loss. NOTE: Single RBC unit orders are recommended for most situations, with clinical re-assessment prior to additional RBC transfusion. a) Hemoglobin less than 7g/dL: Stable hospitalized patients including critical care unit. (target: up to 9 g/dl). NOTE: Many younger patients safely tolerate lower hemoglobin if normovolemic. b) Hemoglobin less than 8 g/dl: Patients with co-morbid conditions such as acute coronary disease, pulmonary disease, or acute septic shock: (target: up to 10 g/dl). c) Hemoglobin less than 10 g/dl: Significantly symptomatic patient with normal volume status (single RBC unit order is recommended). 4) Post-operative transfusion: a) Hemoglobin less than 7 g/dl (insure adequate volume status prior to RBC transfusion). b) Hemoglobin less than 10 g/dl: RBC transfusion may be appropriate if any of the following are present: organ hypoxia, increased potential for or ongoing blood loss, volume status and risk factors for complications of inadequate oxygenation 5) Hemoglobin less than 10 g/dl and burn patient - at least 10% TBSA burn. A lower transfusion threshold may be appropriate depending on the clinical situation. 6) Other-Specify reason. Outcome Indicators: Improvement in clinical status of patient (relief of symptoms of decreased oxygen carrying capacity) Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 2
3 Improvement in Hgb/Hct (one unit of red cells should raise the Hgb on average 1g/dL or 3% Hct in an adult). Post-transfusion Hgb can be drawn after 1 hour of transfusion if there is no ongoing blood loss in a normovolemic patient. Dosing (adults and children at least 35 kg): RBCs should be transfused based on clinical need. Avoid transfusions based solely on Hgb or Hct value. In the absence of acute hemorrhage, RBC transfusion should be given as single unit. RBC dose in each Massive Transfusion Pack (MTP) is 5 RBC units. Dosing (children less than 35 kg): RBC ml/kg will raise hemoglobin by 2 to 3 g/dl depending on body size (in the absence of acute blood loss). Administration: Non-emergent infusion rate for adults and children 35 kg or above: ml/hr for the first 15 min then ml/hr if well tolerated. Infusion must be complete within 4 hours after issue time. Non-emergent infusion rate for children less than 35 kg: Must be based on patient s clinical status and needs. Transfusion is generally completed within 1-2 hours and must be completed within 4 hours. II. PLATELETS (PLT) How Supplied: All platelets at CMC are leukocyte-reduced single donor apheresis. A unit has at least 3 x platelets. Units are stored at room temperature for up to 5 days after donation. Volume is ml. Cost: CMC acquisition cost per platelet unit is $645. Cost inclusive of staff time and infusion supplies is estimated at $1300. Utilization Review Guidelines: Platelets are administered for the prevention and treatment of bleeding in patients with thrombocytopenia or platelet function defects. Indications: 1) Prophylaxis in hematology/oncology and other patients with bone marrow suppression: a) Platelet count less than 10,000/μL: Stable patient. b) Platelet count less than 20,000/μL: Risk factors for bleeding (h/o bleeding, infection, fever, sepsis, disseminated intravascular coagulopathy, qualitative function defect). 2) Prophylaxis for Interventional Radiology (IR) Procedures: a) No platelet count requirement: Fine needle and bone marrow aspiration. b) Platelet count less than 25,000/ μl: Paracentesis, thoracentesis, central lines, PICC lines, percutaneous drains, superficial organ biopsy. c) Platelet count less than 35,000/μL: Deep organ core biopsy (e.g., lung and liver), angiogram. d) Platelet count less than 50,000/ μl: Highest risk IR procedures (eg, renal core biopsy, neuraxis procedures such as LP, epidurals). Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 3
4 3) Platelet count less than 50,000/ μl: Active bleeding or prophylaxis for most OR procedures and higher risk endoscopy procedures with significant bleeding risk. 4) Platelet count less than 100,000/μl: Neurosurgical, ophthalmologic or other procedures where microvascular bleeding is high risk. 5) Cardiac Surgery with: a) Platelet count less than 100,000/μL and microvascular bleeding. b) Microvascular bleeding and qualitative Platelet function defect c) Microvascular bleeding and current ROTEM findings indicating isolated or combined defect of platelet function. d) Post-op microvascular bleeding 6) Documented qualitative platelet dysfunction (e.g., drug-induced, uremia, hereditary). 7) Massive transfusion protocol (MTP) includes 5 RBC, 5 plasma, and 1 pheresis platelet in each MTP pack. ROTEM monitoring is recommended to guide therapy. 8) Other-Specify reason. Outcome Indicators: Cessation or reduction of bleeding Rise in platelet count by 20,000-60,000/μl in a 70 kg recipient after transfusion of a single apheresis platelet unit (if measured min post-transfusion). Dosing (adults and children at least 35 kg): Standard dose is one unit. In some cases such as large body size with large platelet count gap from goal, an order for two platelet units is reasonable. Orders above two units will generally require pathologist approval. Dosing (children less than 35 kg): Platelets 5 to 10 ml/kg will raise platelet count by at least 50,000/uL depending on body size of the child. Administration: Non-emergent infusion rate for adults and large children: ml/hr x 15 min, then ml/hr if well tolerated). Infusion must be complete within 4 hours of issue time. Non-emergent infusion rate for children < 35 kg: Must be based on patient s clinical status and needs. Transfusion is generally completed within 1-2 hours and must be completed within 4 hours. Comments: Platelet function defect should be documented by laboratory assessment of platelet function; or presumed due to hypothermia or mechanical devices that affect platelet function. Tests available include: o ROTEM : Assess both overall platelet function and coagulation factor functionality (Note: available at CRMC) o VerifyNow-P2Y12: Assess P2Y12 inhibitors such as clopidogrel (PLAVIX) and ticagrelor (BRILINTA). o VerifyNow-Aspirin: Asses aspirin effect on platelet function. Not for use in patients also taking other anti-platelet agents. o PFA-100: Assess intrinsic defects such as von Willebrand disease and aspirin medications. o Note: IV GPIIb/IIIa inhibitors may or may not cause abnormal ROTEM, PFA-100 or VerifyNow results. Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 4
5 Recommendations for stopping medication prior to invasive procedures vary with the medication and clinical situation. Platelet function tests may help assess level of platelet inhibition and safe timing of surgical procedure. Consider DDAVP in addition to administration of platelets to control bleeding. III. PLASMA (FFP) How Supplied: Fresh Frozen Plasma (FFP) or Fresh Plasma 24 (FP24): Plasma prepared from either a whole blood or apheresis collection and frozen either within 8 hours or 24 hours of collection. o Can be used interchangeably all are referred to as Plasma o Contains similar levels of clotting factors Thawed plasma: Unit of FFP or FP24 that was thawed and stored at 1-6 C for 1-5 days o Considered therapeutically equivalent to FFP/FP24 for most indications. Cryo-poor plasma: Prepared from FFP after cryoprecipitate is removed. o Contains limited or no factor VIII and XIII, vwf, fibrinogen, or fibronectin o Used solely in the treatment of thrombotic thrombocytopenic purpura Volume per unit is ml Cost: CMC acquisition cost per FFP unit is $75. Cost inclusive of staff time and infusion supplies is estimated at $150. Utilization Review Guidelines: Plasma transfusion therapy is indicated for treatment of documented coagulopathy, where the mechanism for coagulation defect is known, understood and attributable to coagulation factor deficiency, and it is expected that replacement with plasma transfusion is the most efficient way to correct that deficiency. PT/INR, PTT, and ROTEM analysis are indicative of the severity of coagulation defect. Indications: 1) Active Bleeding: a) INR greater than 1.7. b) ROTEM showing significantly abnormal INTEM, EXTEM CT, CFT, alpha angle 2) Prophylaxis for Interventional Radiology procedures: a) INR greater than 1.5: Highest risk IR procedures (e.g., renal core biopsy, neuraxis procedures such as LP, epidurals). b) INR greater than 1.7: Deep organ core biopsy (e.g., lung and liver) and angiogram. c) INR greater than 2.0: Thoracentesis, central lines, PICC lines, percutaneous drains, superficial organ biopsy. d) INR greater than 3.0: Paracentesis, bone marrow biopsy. e) No coagulation testing required: Fine needle aspiration 3) Prophylaxis for moderate to high risk operating room and endoscopy procedures: a) INR greater than 1.7. b) ROTEM showing abnormal INTEM, EXTEM CT, CFT, alpha angle (ROTEM may also enter into pre-ir transfusion decisions). 4) Prophylaxis for lower risk surgical procedures, endoscopy with biopsy, a) INR greater than 2.0 b) ROTEM showing significantly abnormal INTEM, EXTEM CT, CFT, alpha angle. 5) INR greater than 1.5: Intracranial or spinal bleeding or planned neurosurgical procedure. Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 5
6 6) Massive transfusion protocol (MTP) includes 5 RBC, 5 plasma, and 1 pheresis platelet in each MTP pack. ROTEM monitoring is recommended to guide therapy. 7) Emergent reversal of warfarin in a patient with active bleeding or when bleeding could be catastrophic (e.g. intracranial hemorrhage). a) For non-urgent surgical procedures, Vitamin K should be used to reverse warfarin effect unless therapeutic anticoagulation is again rapidly needed post-procedure. b) Instead of plasma consider Prothrombin complex concentrate (FEIBA) for lifethreatening bleed (e.g. intracranial hemorrhage) see U2010/PRL 10 (Hemostatic medications for trauma/anticoagulated patients presenting with life-threatening hemorrhage). 8) Disseminated Intravascular Coagulopathy (DIC) with active bleeding. Consider administration of cryoprecipitate if fibrinogen or ROTEM FIBTEM is low. 9) Replacement fluid for plasma exchange (therapeutic apheresis) procedure. 10) Replacement of single factor deficiencies for which no single factor concentrate product is available (e.g. factor XI, V deficiency). This is very rare. 11) Other-Specify reason. Outcome Indicators: Cessation or reduction of coagulopathic bleeding. Reduction of INR or improved ROTEM Dosing (adults and children at least 35 kg): ml/kg (typically 2-4 units for adults). Dosing (children less than 35 kg): ml/kg (whole units are issued from which specific volume can be infused) Administration: Non-emergent infusion rate for adults and children at least 35 kg: ml/hr x 15 min, then ml/hr if well tolerated. Infusion must be complete within 4 hours of issue time. Non-emergent infusion rate for children less than 35 kg: Must be based on patient s clinical status and needs. Transfusion is generally completed within 1-2 hours and must be completed within 4 hours. IV. CRYOPRECIPITATE (CRYO) How Supplied: Cryoprecipitate is distributed as a pool of 5 units or as single units. Cryoprecipitate contains factor VIII, von Willebrand factor, fibrinogen and factor XIII. Cryoprecipitate must have at least 150 mg fibrinogen/unit (on average at CMC it has at least 200 mg fibrinogen/unit). Volume of a 5-unit pool is about 100 ml. Cost: CMC acquisition cost per two 5-packs units (10 unit order) is $650. Cost inclusive of staff time and infusion supplies is estimated at $1600. Utilization Review Guidelines: Cryoprecipitate transfusion therapy is indicated for treatment of documented coagulopathy where the mechanism for coagulation defect is known, understood and attributable to fibrinogen, factor VIII or XIII, or von Willebrand factor deficiency, and it is expected that replacement with Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 6
7 cryoprecipitate transfusion is the most efficient way to correct that deficiency. Fibrinogen level and ROTEM FIBTEM analysis measure severity of coagulation defect for common scenarios. Indications: 1) Active bleeding, peripartum, or prior to moderate-to high-risk invasive procedure: a) And fibrinogen less than 100 mg/dl. b) Or ROTEM showing significantly low FIBTEM. c) Assess also the need for plasma and platelets. 2) Massive transfusion protocol: Cryoprecipitate is not routinely supplied, but should be considered after the patient has received 1 to 2 MTP boxes. ROTEM tubes are supplied with 2 nd box to encourage monitoring. 3) Liver disease with dysfibrinogenemia and active bleeding 4) Factor XIII deficiency and active bleeding; specific factor concentrate is preferred. 5) Uremic bleeding; DDAVP is preferred. 6) Other-Specify reason. Outcome Indicators: Fibrinogen level increases to at least 100 mg/dl. Cessation of coagulopathic bleeding. Dosing (adults and children t least 35 kg): Choices are 5 units or 10 units in an adult (to best approximate one unit per 7-10 kg). Due to high fibrinogen content of our cryo, 10 units is maximum single order dose. 10 units will raise fibrinogen by 50 to 100 mg/dl in an average size adult. Dosing (children less than 35 kg): 1 to 2 single units per 10 kg will raise fibrinogen by 60 to 100 mg/dl. Administration: As rapidly as tolerated. Comments: Fibrinogen threshold of less than 100 mg/dl is often stated, however, this value has not been rigorously defined in clinical trials. Similarly, the precise ROTEM FIBTEM value for decision point is not defined. When there is coagulopathic bleeding, cryo may be efficacious even if FIBTEM is in low normal range, but also consider plasma and/or platelets. Not indicated in hemophilia A or von Willebrand Disease (vwd). In patients with congenital fibrinogen deficiency (afibrinogenemia, hypofibrinogenemia) with acute bleeding or surgery, use fibrinogen concentrate if available. V. GRANULOCYTES Comments 1) Data for some clinical indications are inconclusive. Granulocytes are rarely transfused in the modern era of powerful marrow stimulants such as G-CSF. Some clinical utility may exist in neonatal patients with sepsis. 2) All requests for granulocyte transfusion must be discussed with the Transfusion Service Medical Director or another Pathologist. Because of the rarity of this component it may not be available in a timely manner. 3) All Granulocyte products are irradiated. Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 7
8 NEONATAL TRANSFUSION GUIDELINES - INFANTS < 4 MONTHS I. RED BLOOD CELLS (RBC) - INFANTS < 4 MONTHS Indications: 1) Blood loss that totals > 10% of blood volume in the critically ill, extremely low birth weight (<1000 grams) infant that is a relative indication depending on hemodynamic stability, need for vasopressor infusions (ie, dopamine), renal function, pulmonary function (ie, need for mechanical ventilation), and disease prosesses (ie, sepsis) associated with increased oxygen consumption. Blood loss > 10% is not an absolute indication for transfusion of red blood cells. 2) Symptomatic anemia, indicating primarily by persistence tachycardia (HR > 170). Symptoms may also include difficulty feeding, poor weight gain, and/or excessive apnea/bradycardia. Generally, if such symptoms are related to anemia, one would expect the hematocrit to be below 25% in infants not on supplemental oxygen and below 30% in infants requiring supplemental oxygen. 3) Anemia (hematocrit < 30%) in the presence of conditions that increase tissue oxygen consumption (ie, sepsis). 4) Heart disease in which transfusion is given to decrease cardiac workload or improve tissue oxygen delivery. 5) Intraoperative requirement clinically determined by anesthesiologist and/or surgeon. 6) Postoperative to restor hemodynamic stability when other types of fluid replacement have been inadequate or when the hemodynamic instability is sufficiently life-threatening. II. III. PLATELETS (PLT) - INFANTS < 4 MONTHS Indications 1) Thrombocytopenia (platelet count < 30,000/μL) in the presence of bleeding or disseminated intravascular coagulation. 2) Intraoperative requirement clinically determined by anesthesiologist and/or surgeon. 3) Postoperative hemorrhage that is not reasonable attributed to a discrete anatomic bleeding source or to coagulopathy. 4) Profoundly low platelet count (< 20,000/ μl), even in absence of active bleeding. PLASMA (FFP) AND CRYOPRECIPITATE (CRYO) - INFANTS < 4 MONTHS Indications 1) Documented disseminated intravascular coagulation. Fibrinogen < 150 mg/dl and elevated FDPs. 2) A clinical condition (ie, sepsis, necrotizing enterocolitis, significant blood loss) strongly associated with disseminated intravascular coagulation. 3) A clinical condition strongly associated with capillary leak syndrome. 4) Intraoperative requirement clinically determined by anesthesiologist and/or surgeon. 5) Postoperative hemorrhage. 6) Replacement therapy. Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 8
9 SPECIAL BLOOD PRODUCT/COMPONENT MODIFICATIONS I. IRRADIATION OF CELLULAR BLOOD COMPONENTS Include request as part of RBC and Platelet Orders. There may be a several hour delay in availability. Irradiation of cellular blood components (RBC and platelets) is highly effective in preventing the lymphocyte proliferation that rarely causes graft-versus-host disease (GVHD) in immunosuppressed transfusion recipients. Leukocyte reduction alone is not effective in the prevention of GVHD. In general, the risk of GVHD is proportional to the severity of immune deficiency. Given the rarity of GVHD, risks associated with some of the factors below are not well characterized, and expert opinions vary about some of these indications. 1) Absolute and Probable Indications (Neonatal/Pediatric): NOTE: ALL RBC and platelets issued for infants less than 4 months of age at CRMC and CCMC are irradiated whether or not ordered in EPIC. The same is true for intrauterine cellular transfusions. a) Intra-uterine transfusion recipients. b) Highly premature newborns (less than 1200 gm). c) Recipients of neonatal exchange transfusion. d) Term newborns on extracorporeal membrane oxygenators. e) Congenital cellular immunodeficiency syndrome patients. 2) Absolute and Probable Indications (Hematologic/Oncologic/Transplant): a) Recipients of autologous or allogeneic hematopoietic stem cell transplants. b) Recipients of solid organ transplants (this is controversial). c) Patients with active or past history of Hodgkin lymphoma or non-hodgkin lymphoma, whether or not currently under treatment. d) Patients with hematologic malignancies such as acute leukemia and myelodysplasia treated with cytotoxic agents, whether or not currently under treatment. e) Patients with certain solid tumors such as neuroblastoma, rhabdomyosarcoma and glioblastoma under treatment. f) Patients receiving high dose chemotherapy, radiation therapy and/or aggressive immunotherapy, including all patients with current or past exposure to fludarabine, other purine analogues, alemtuzumab (Campath), or anti-thymocyte globulin therapy. 3) Absolute and Probable Indications (Related to transfusion of certain components): a) Granulocyte transfusions. b) HLA-matched components or any cellular components from biologic relatives. c) Crossmatch-compatible platelets. 4) No established indications: a) Patients with AIDS or HIV, unless one of the above indications applies. b) c) Patients with aplastic anemia not receiving immuno-suppressive therapy. Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 9
10 d) Patients without malignancy (such as those with autoimmune diseases) receiving immunosuppressive medications other than fludarabine or other purine analogues. e) Elderly and pregnant patients, unless one of the above indications applies. II. CYTOMEGALOVIRUS (CMV)-NEGATIVE COMPONENTS While there is not universal agreement, some data and standard practice support the clinical equivalence of pre-storage leukocyte-reduced RBC and platelets to CMV negative blood components. Pre-storage leukocyte-reduced blood components are used for all transfusions in Community Medical Centers (CMC) facilities. CMV transmission is generally not thought to be a factor with non-cellular components such as plasma and cryoprecipitate. NOTE: Granulocyte transfusions to CMV negative or CMV untested patients should be from a CMV negative donor, if feasible. EXCEPTION: By agreement with CMC hematologist-oncologist physicians the following patients should receive RBC and platelets that test CMV negative (in addition to being leukoreduced). Any substitution with CMV untested components requires the approval of the ordering physician. 1) Newly diagnosed leukemia/lymphoma/myeloma/aplasia/myelodysplasia patients, whose CMV status is not yet known. 2) Patients who may be allogeneic stem cell transplant candidates and whose CMV status is not yet known. 3) Patients known to be CMV negative, who are potential candidates for allogeneic stem cell transplant or have previously undergone allogeneic transplant. III. SICKLE CELL-NEGATIVE RED BLOOD CELLS (RBC) It is CMC Laboratory policy to automatically provide sickle cell hemoglobin negative RBC products for all neonatal and intrauterine transfusions including exchange and replacement transfusions. The ordering provider should also request screened, sickle cell negative RBCs for patients known clinically to have a sickle hemoglobin disorder (ie, SS, SC, S-thalassemia, including heterozygous sickle trait patients). Initial identification of sickle cell negative RBCs usually relies on communication from the ordering provider. Once the blood bank is aware of the need, this documentation will be included in the patient blood bank for future reference. IV. SPECIAL PLATELET ORDERS FOR REFRACTORY PATIENTS (CROSSMATCHED/HLA MATCHED) 1) General Comments: a) Crossmatched and/or HLA Matched platelets may be beneficial for the patient who is immunologically refractory to platelets. The usual definition of platelet refractoriness is two consecutive 60 minute post-transfusion platelet count increments of less-than 5,000 /ul. The 60-minute post-transfusion platelet count is very important to the assessment of immunologic refractoriness. If the 60 minute increment is above this value but the count drops off after that, the refractoriness is likely to be due to a non-immune factor such as medications, infection, splenomegaly. b) Once immune refractoriness has been documented, start the process for crossmatched platelets. If the patient does not respond, request HLA-matched platelets. Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 10
11 c) Orders for Crossmatched and/or HLA matched Platelets must be coordinated with the Transfusion Service Laboratory. It takes at least one day to obtain them, as they are not sourced locally. d) Crossmatched and/or HLA Matched Platelet products are irradiated. 2) Crossmatched platelets a) Crossmatched platelets are more convenient and economical than HLA matched ones. b) If HLA typing cannot be done due to leukopenia, this is only choice for the refractory patient. 3) HLA Matched Platelets. a) The HLA type of all patients who will receive long-term platelet support should be performed before they are rendered pancytopenic by therapy. WBC count must be >1.0x103/ul for typing. b) HLA Matched Platelets may be required if most of the attempted crossmatched Platelet products are positive. V. PRE-OPERATIVE AUTOLOGOUS BLOOD DONATION (PAD) 1) Interest in PAD has declined dramatically in recent years. High wastage rates (unused autologous blood cannot be given to other patients), higher risk of coming to surgery significantly anemic, along with improved safety of the blood supply (with respect to infectious disease transmission) have all contributed to its lower use. 2) PAD may be a reasonable option for patients with rare blood types or multiple antibodies, or who refuse donor blood. 3) PAD requires advance planning, with collection ideally 4-6 weeks before anticipated need, to mitigate the anemia induced by it. 4) NOTE: The State of California does require that physicians discuss alternatives to allogeneic transfusion (including autologous donation and the largely discredited idea of directed donations from chosen donors), with patients for whom it may be an option. This does not mean that the surgeon should recommend autologous donation to the patient. This is the Paul Gann Blood Safety Act (Health and Safety Code Section1645). The mandated patient handout, A Patient s Guide to Blood Transfusion is stocked in CMC hospitals and is available at the Medical Board of California web site. Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 11
12 BLOOD PRODUCTS--SPECIAL TRANSFUSION ORDER GUIDANCE I. BLOOD WARMING 1) General Blood Warmer Notes: a) A physician must order use of a blood warmer unless it is routinely part of operating room protocol (eg, trauma and cardiac cases). b) Blood warming is not needed or recommended for platelets or cryoprecipitate. Avoid infusion through the blood warming device, when feasible. 2) American Association of Blood Banks (AABB) recommends the following indications: a) Massive transfusions. b) Trauma situations in which core-rewarming measures are indicated. c) Administration rate of PRBC and/or plasma greater than 50 ml/min for 30 min or more (adults) or greater than 15 ml/min/kg/hour (children). d) Exchange transfusion of a newborn. e) Patient rewarming phase during cardiopulmonary by-pass surgery. 3) AABB guidelines recommend consideration of blood warming in the following situations: a) Packed RBC transfusion in the presence of potent high-titered cold agglutinins reactive at body temperature and capable of binding complement thereby causing hemolysis. b) Raynaud's syndrome. c) Neonatal and pediatric transfusions. d) Warming is definitely indicated for RBC exchange transfusion of newborns. e) Therapeutic apheresis procedures. II. PREMEDICATION TO PREVENT TRANSFUSION REACTIONS Simple (non-hemolytic, non-septic) febrile reactions and allergic reactions (the large majority of which are cutaneous only) may complicate at least 1% of transfusions. With the exception of IgA and haptoglobin deficiency it is not usually possible to define antigen(s) to which patient is reacting. Most expert guidance is to premedicate only if a patient has experienced more than one bona fide such reaction. Routine use of premedication for all patients is not advocated by experts or supported by evidence. 1) Febrile reaction: Recommend acetaminophen at least 30 min prior to transfusion. 2) Allergic reaction: a) Premedication with antihistamine (eg, mg diphenhydramine) 30 min prior to transfusion may be helpful in patients with history of either severe or multiple non-severe allergic reactions. b) Routine premedication may be considered in patients undergoing multiple high volume plasma exposures, eg, therapeutic plasmapheresis, but is not otherwise indicated. c) If antihistamines are not sufficient prednisone (20-50 mg orally) or parenteral steroid may be used. d) Patients with current or history of severe allergic reactions should be discussed with the blood bank. Additional testing (eg, to explore possible IgA or haptoglobin deficiency) or plasma volume reduction, may be indicated. Transfusion Guidelines, Revised 7/2014, Approved MEC 8/2014 Page 12
Blood Components & Indications for Transfusion. Neda Kalhor
Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationGUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS
CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA Introduction: GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS These guidelines have been developed in conjunction with the hospital Transfusion Committee.
More informationLifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.
LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA 1011.02 Transfusion Criteria Version#2 Department POLICY NO. PAGE NO. Blood Bank Quality Assurance Manual
More informationEffective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)
1 of 5 Policy #: 702 (PHL-702-05) Effective Date: 9/30/2004 Reviewed Date: 8/1/2016 Subject: TRANSFUSION GUIDELINES Approved by: Laboratory Director, Jerry Barker (electronic signature) Approved by: Laboratory
More informationPOLICY NO. Printed copies are for reference only. Please refer to the electronic copy for the latest version.
Department Blood Bank POLICY NO. 4633 Department Of Pathology LBH Transfusion Criteria Version# 2 PAGE NO. 1 OF 9 Printed copies are for reference only. Please refer to the electronic copy for the latest
More informationCrackCast Episode 7 Blood and Blood Components
CrackCast Episode 7 Blood and Blood Components Episode Overview: 1) Describe the 3 categories of blood antigens 2) Who is the universal donor and why? 3) Define massive transfusion 4) List 5 physiologic
More informationBlood Component Therapy
Blood Component Therapy Dr Anupam Chhabra Incharge-Transfusion Medicine Pushpanjali Crosslay Hopital NCR-Delhi Introduction Blood a blood components are considered drugs because of their use in treating
More informationADULT TRANSFUSION GUIDELINES ORDERED COMPONENT
ADULT TRANSFUSIN GUIDELINES RDERED Packed red cells (RBCs) RBCs, WBCs, platelets & plasma (minimal) Increase red cell mass and oxygen carrying capacity; generally indicated when Hgb is 7 gm or Hct 21 unless
More informationBlood Components Transfusion Criteria
Adults 1. Packed Cells: Dosage one unit of red blood cells will raise the Hbg by 1 gram; Hct by 3% in a 70Kg adult. Red Blood Cells should be transfused based on clinical need. In the absence of acute
More informationUKGS TRANSFUSION SERVICE PRODUCTS AND AVAILABILITY
Lexington, KY Page 1 of 13 Affected Sites: Enterprise Chandler X Good Samaritan I. PRINCIPLE: The UK Good Samaritan Hospital is dedicated to serve the patients with safe, high quality blood products and
More informationMASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE
MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE CONTENTS Definition Indications Transfusion trigger Massive transfusion protocol Complications DEFINITION Massive transfusion:
More informationBassett Medical Center The Mary Imogene Bassett Hospital Clinical Laboratory Blood Bank Title: Blood Transfusion Guidelines 2016 Revision: 1 Created
Bassett Medical Center The Mary Imogene Bassett Hospital Clinical Laboratory Blood Bank Title: Blood Transfusion Guidelines 2016 Revision: 1 Created By: Bray, Karen Last Approved Time: 7/22/2016 12:41:34
More informationBlood Product Modifications: Leukofiltration, Irradiation and Washing
1. Leukocyte Reduction Definitions and Standards: o Process also known as leukoreduction, or leukofiltration o Applicable AABB Standards, 25th ed. Leukocyte-reduced RBCs At least 85% of original RBCs
More informationGUIDELINES FOR IRRADIATED BLOOD COMPONENTS
GUIDELINES FOR IRRADIATED BLOOD COMPONENTS 1. Policy Statement 2. Definitions 1.1 Blood transfusion services shall have a policy which indicates recipients who are to receive irradiated blood components.
More informationCrossmatching and Issuing Blood Components; Indications and Effects.
Crossmatching and Issuing Blood Components; Indications and Effects. Alison Muir Blood Transfusion, Blood Sciences, Newcastle Trust Topics Covered Taking the blood sample ABO Group Antibody Screening Compatibility
More informationRisk of ID transmission. Patient Blood Management - Blood Safety and Component Utilization. Transfusion and Cancer 4/9/2014
Patient Blood Management - Blood Safety and Component Utilization Lowell Tilzer M.D. Pathology and Lab Medicine Kansas University Med Center Risk of ID transmission Pre NAT Post NAT HIV 1:607,000 ~1:2.5
More informationTransfusion Medicine Best Practices: Indications for Blood Components
Transfusion Medicine Best Practices: 1.0 Policy Statements 1.1 Regional Health Authorities (RHAs) shall develop policies, processes and procedures for ordering, distribution, storage, transfusion and administration
More informationBlood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD
Blood transfusion Dr. J. Potgieter Dept. of Haematology NHLS - TAD General Blood is collected from volunteer donors >90% is separated into individual components and plasma Donors should be: healthy, have
More informationTransfusion Medicine III
Transfusion Medicine III Blood Products from Collection to Use D. Joe Chaffin, MD Loma Linda University 3/5/2019 FFP WB RBC Anticoagulant/Preservatives Why we need 21 Day Shelf Life Prevent clotting Keep
More informationBlood Transfusion. What is blood transfusion? What are blood banks? When is a blood transfusion needed? Who can donate blood?
What is blood transfusion? A blood transfusion is a safe, common procedure in which blood is given through an intravenous (IV) line in one of the blood vessels. A blood transfusion usually takes two to
More informationAssessing thrombocytopenia in the intensive care unit: The past, present, and future
Assessing thrombocytopenia in the intensive care unit: The past, present, and future Ryan Zarychanski MD MSc FRCPC Sections of Critical Care and of Hematology, University of Manitoba Disclosures FINANCIAL
More informationBlood Product Utilization A Mythbusters! Style Review. Amanda Haynes, DO 4/28/18
Blood Product Utilization A Mythbusters! Style Review Amanda Haynes, DO 4/28/18 Objectives Describe concepts in Patient Blood Management Review common misconceptions surrounding blood transfusion Summarize
More informationConsent Laboratory Transfuse RBC
Peds Blood Product Infusion Order Set (386) [386] Blood product review will be performed unless exclusion criteria met. MD: Please note if transfusion giv en outside of parameter, please justify use in
More information2/2/2011. Blood Components and Transfusions. Why Blood Transfusion?
Blood Components and Transfusions Describe blood components Identify nursing responsibilities r/t blood transfusion Discuss factors r/t blood transfusion including blood typing, Rh factor, and cross matching
More informationSpecific Requirements
Specific Requirements AIMS Specific requirements your patients have for transfusion and how this is managed Classify which patients require: Irradiated components CMV negative components Washed components
More informationApproach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
More informationThe primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:
Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist
More informationUnit 5: Blood Transfusion
Unit 5: Blood Transfusion Blood transfusion (BT) therapy: Involves transfusing whole blood or blood components (specific portion or fraction of blood lacking in patient). Learn the concepts behind blood
More informationTRANSFUSIONS FIRST, DO NO HARM
TRANSFUSIONS FIRST, DO NO HARM BECAUSE BLOOD CAN KILL 7 TRALI DEATHS SINCE 2002 WMC 5 women BECAUSE In OB you are transfusing 2 instead of 1 BECAUSE BLOOD IS A LIQUID TRANSPLANT RISKS versus BENEFITS versus
More informationComponents of Blood. N26 Blood Administration 4/24/2012. Cabrillo College ADN/C. Madsen RN, MSN 1. Formed elements Cells. Plasma. What can we give?
Components of Blood Formed elements Cells Erythrocytes (RBCs) Leukocytes (WBCs) Thrombocytes (platelets) Plasma 90% water 10% solutes Proteins, clotting factors 1 What can we give? Whole blood Packed RBC
More informationPediatric massive transfusion protocols
University of New Mexico UNM Digital Repository Emergency Medicine Research and Scholarship Emergency Medicine 2014 Pediatric massive transfusion protocols Ramsey Tate Follow this and additional works
More informationBlood is serious business
Transfusion at RCH BLOOD TRANSFUSION Anthea Greenway Dept of Clinical Haematology >10000 fresh blood products per year Supports craniofacial and cardiac surgery Support bone marrow, liver transplant and
More informationBLOOD TRANSFUSION. Dr Lumka Ntabeni
BLOOD TRANSFUSION Dr Lumka Ntabeni Blood transfusion definition SAFE transfer of BLOOD COMPONENTS from a DONOR to a RECEPIENT CONTENT Brief history of blood transfusion How is safety guaranteed? How do
More informationChapter 46. Care of the Patient with a Blood or Lymphatic Disorder
Chapter 46 Care of the Patient with a Blood or Lymphatic Disorder All items and derived items 2015, 2011, 2006 by Mosby, Inc., an imprint of Elsevier Inc. All rights reserved. Components of the Blood Red
More informationA Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients. Chris Kim 11/29/12
A Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients Chris Kim 11/29/12 Background Prevention of TAGVHD Irradiation: induces DNA crosslinks,
More informationChapter 13 The Blood
Chapter 13 The Blood Copyright 2015 Wolters Kluwer Health Lippincott Williams & Wilkins Overview Key Terms agglutination erythrocyte lymphocyte albumin fibrin megakaryocyte anemia hematocrit monocyte antigen
More informationChapter 3 Diseases of the Blood and Bloodforming Organs and Certain Disorders Involving the Immune Mechanism D50-D89
Chapter 3 Diseases of the Blood and Bloodforming Organs and Certain Disorders Involving the Immune Mechanism D50-D89 Presented by Jennifer Kurkulonis 1 FOUR MAJOR TYPES OF BLOOD CELLS White blood cells
More informationTransfusion Reactions. Directed by M-azad March 2012
Transfusion Reactions Directed by M-azad March 2012 Transfusion Reactions are Adverse reactions associated with the transfusion of blood and its components Transfusion reactions Non-threatening to fatal
More informationTransfusion Pitfalls. Objectives. Packed Red Blood Cells. TRICC trial (subgroups): Is transfusion always good? Components
Objectives Transfusion Pitfalls Gregory W. Hendey, MD, FACEP Professor and Chief UCSF Fresno, Emergency Medicine To list risks and benefits of various blood products To discuss controversy over liberal
More informationImmunological transfusion reactions
Immunological transfusion reactions Immunological transfusion reactions can be hemolytic or non-hemolytic in nature. Both types can be separated into acute (those occurring immediately after transfusion)
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationCOMPLICATIONS OF BLOOD TRANSFUSIONS. :Prepared by Dr. Nawal Mogales & Dr. Mohammed Aqlan
COMPLICATIONS OF BLOOD TRANSFUSIONS :Prepared by Dr. Nawal Mogales & Dr. Mohammed Aqlan COMPLICATIONS OF TRANSFUSIONS Transfusion reaction may result from either : A. Immune transfusion reaction. B. Non
More informationLearning Objectives. Blood Component Therapy. Blood Component Therapy. Apheresis Technology. Red Cells
Learning Objectives Blood Component Therapy Jeffrey Jhang, MD Assistant Professor of Clinical Pathology College of Physicians and Surgeons New York, NY 1. Know how components are prepared by whole blood
More information12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization
Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,
More informationChest diseases Hospital Laboratory Hematology Practice guidelines
Chest diseases Hospital Laboratory Hematology Practice guidelines Title RBCs transfusion in Adults SOP Code Policy Owner Hematology Unit Section Hematology Prepared By Dr. Taher Ahmed Abdelhameed Issuing
More informationAn Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD
Harold Alvarez, MD Objectives Explain the etiology of platelet refractoriness Discuss the different types of platelet refractoriness Describe how platelet refractoriness is diagnosed Discuss different
More informationNew Advances in Transfusion EM I LY CO BERLY, M D
New Advances in Transfusion EM I LY CO BERLY, M D TRANSFUSI ON M EDI CI NE FELLO W VANDERBI LT UNI VERSITY Objectives To discuss the terminology, components, transfusion risks, and dosing guidelines for
More informationTransfusion 2004: Current Practice Standards. Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service
Transfusion 2004: Current Practice Standards Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service Massive Transfusion Protocol (MTP) When should it be activated? Massive bleeding i.e. loss of one blood
More informationTransfusion Therapy & Safety. Mary Grabowski, RN, BSN, BSIA Transfusion Safety Officer PSONEC Fundamentals September, 2015
Transfusion Therapy & Safety Mary Grabowski, RN, BSN, BSIA Transfusion Safety Officer PSONEC Fundamentals September, 2015 Topics Blood Components Special Processing/Attributes Irradiation Leukoreduction
More informationBassett Medical Center The Mary Imogene Bassett Hospital Clinical Laboratory Blood Bank Title: MTP 2016 Revision: 2.00 Created By: Admin, The Last
Bassett Medical Center The Mary Imogene Bassett Hospital Clinical Laboratory Blood Bank Title: MTP 2016 Revision: 2.00 Created By: Admin, The Last Approved Time: 7/22/2016 12:44:54 PM Massive Transfusion
More informationCoagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
More informationTransfusion: indications (RBC, platelets, granulocytes, plasma)
Transfusion: indications (RBC, platelets, granulocytes, plasma) BHS Educational Course: course n 5 22/3/2014 Timothy Devos (KU Leuven) Indications for the transfusion of erythrocytes General rules only
More informationHeme (Bleeding and Coagulopathies) in the ICU
Heme (Bleeding and Coagulopathies) in the ICU General Topics To Discuss Transfusions DIC Thrombocytopenia Liver and renal disease related bleeding Lack of evidence in managing critical illness related
More informationACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology
ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology ACGME approved: June 27, 2006; effective: July 1, 2007 ACGME approved focused revision: September 30, 2012; effective:
More informationGuidelines for Gamma Irradiation of Blood Components
AUSTRALIAN & NEW ZEALAND SOCIETY OF BLOOD TRANSFUSION INC. AUSTRALIAN RED CROSS BLOOD SERVICE NEW ZEALAND BLOOD SERVICE Guidelines for Gamma Irradiation of Blood Components Revised 2003 AN ZS B T Australian
More informationThe ABC s of Blood Components. Terry Downs, MT(ASCP)SBB Administrative Manager University of Michigan Hospitals Blood Bank and Transfusion Service
The ABC s of Blood Components Terry Downs, MT(ASCP)SBB Administrative Manager University of Michigan Hospitals Blood Bank and Transfusion Service Objectives Describe three additives used in blood components.
More informationLearning Objectives: At the end of this exercise, the student will be able to:
Applications in Transfusion Medicine- A CBL Exercise- Student Guide 1 Title: Applications in Transfusion Medicine A CBL Exercise Purpose: At the conclusion of this exercise, students will be able to apply
More informationCASE STUDIES IN CLINICAL APPLICATIONS OF THERAPEUTIC PLASMA EXCHANGE
CASE STUDIES IN CLINICAL APPLICATIONS OF THERAPEUTIC PLASMA EXCHANGE Eric Rosa, MLS (ASCP) CM Medical Laboratory Scientist Transfusion Service April 18, 2018 Objectives Explain the process of a therapeutic
More informationBlood/Blood Component Utilization and Administration Annual Compliance Education
Blood/Blood Component Utilization and Administration Annual Compliance Education This course contains annual compliance education necessary to meet compliance and regulatory requirements. Instructions:
More informationDr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN
Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN The student should be able:» To identify the mechanism of homeostasis and the role of vessels, platelets
More informationApproach to a patient with suspected blood transfusion reaction. Raju Vaddepally, MD
Approach to a patient with suspected blood transfusion reaction Raju Vaddepally, MD Goals Detection of Acute Transfusion Reactions (ATR) Clinical and Laboratory Evaluation of ATR Management of individual
More informationHEME 10 Bleeding Disorders
HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional
More informationRENAL & HEMATOLOGY EMERGENCIES JEFF SIMONS B.S. F-PC
RENAL & HEMATOLOGY EMERGENCIES JEFF SIMONS B.S. F-PC GOALS Overview of renal system anatomy / physiology Discuss common medical / trauma renal issues Identify associated assessment keys GOALS Introduction
More informationHEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Hematology MOC exam blueprint Based on feedback from physicians that MOC assessments should
More informationTRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
More informationQUICK REFERENCE Clinical Practice Guide on Red Blood Cell Transfusion
QUICK REFERENCE 2012 Clinical Practice Guide on Red Blood Cell Transfusion Presented by the American Society of Hematology, adapted from Red Blood Cell Transfusion: A Clinical Practice Guideline from the
More informationPreferred Clinical Services for Leading Age Florida August 26-27, 2015
DIAGNOSIS CODING ESSENTIALS FOR LONG-TERM CARE: CHAPTER 3, D CODES DISEASES OF THE BLOOD AND BLOOD-FORMING ORGANS AND CERTAIN DISORDERS INVOLVING THE IMMUNE MECHANISM Preferred Clinical Services for Leading
More informationPretransfusion Testing
Pretransfusion Testing Blood transfusion services The immunohematologic testing needed for By proper patient blood typing, component Dr. selection Reham and Talaat compatibility testing. Which Blood ensure
More informationUse of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference
Use of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference John A. Aucar, MD, MSHI, FACS, CPE EmCare Acute Care Surgery Del Sol Medical Center Associate Professor, University
More informationNicole Laferriere MD PhD FRCPC April 10, Patient Case Studies: Sticky Situations For Platelet Transfusions
Nicole Laferriere MD PhD FRCPC April 10, 2019 Patient Case Studies: Sticky Situations For Platelet Transfusions Disclosures Ad Board: Celgene, Jansen, Takeda, Roche, Sanofi, Leo, Shire, Servier, Phizer,
More informationPHYSIOLOGY AND MANAGEMENT OF THE SEPTIC PATIENT
PHYSIOLOGY AND MANAGEMENT OF THE SEPTIC PATIENT Melanie Sanchez, RN, MSNE, OCN, CCRN Clinical Nurse III City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES LAS VEGAS, NV
More informationLahey Clinic Internal Medicine Residency Program: Curriculum for Hematology
Lahey Clinic Internal Medicine Residency Program: Curriculum for Hematology Faculty representative: Neil Weiner, MD Resident representative: Guiherme Rabinowits, MD Revision date: February 28, 2006 Goals
More informationMassive Transfusion. MPQC Spring Summit April 29, Roger Belizaire MD PhD
Massive Transfusion MPQC Spring Summit April 29, 2015 Roger Belizaire MD PhD Take home points 1. Blood is always available. Requests for massive transfusion or emergency release typically only require
More informationHaematology and Transfusion
Haematology and Transfusion dr.w.engelhardt@gmail.com Wolfram Engelhardt Offenburg, Germany James Blundell 1828 Diameter 6-8 µm Erythrocytes Women: Men: 4-5 x 10 6 /µl 5-6 x 10 6 /µl live 100-120 days
More informationHematologic changes in systemic diseases. Chittima Sirijerachai
Hematologic changes in systemic diseases Chittima Sirijerachai Systemic diseases Infection Renal diseases Liver diseases Connective tissue diseases Malignancy Anemia of chronic disease (ACD) Chronic infections:
More informationTransfusion Requirements and Management in Trauma RACHEL JACK
Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acute lymphoblastic leukemia, in India, 439 440 pediatric, global approach to, 420 424 core resources in low- and middle-income countries, 423
More informationQUESTIONS OF HEMATOLOGY AND THEIR ANSWERS
QUESTIONS OF HEMATOLOGY AND THEIR ANSWERS WHAT IS TRUE AND WHAT IS FALSE? Questions 1 Iron deficiency anemia a) Is usually associated with a raised MCV. b) The MCH is usually low. c) Is most commonly due
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationChapter 13 ADVERSE TRANSFUSION EVENTS
Chapter 13 ADVERSE TRANSFUSION EVENTS PRACTICE POINTS The most common severe reaction is ABO incompatibility caused by mis-identification or mis-labelling of the blood component, patient or pre-transfusion
More informationClinical Applications: Donor and Cellular Therapy. Jay S. Raval, MD University of North Carolina Chapel Hill, NC
Clinical Applications: Donor and Cellular Therapy Jay S. Raval, MD University of North Carolina Chapel Hill, NC None Conflicts of Interest Objectives Donor Collections of Red Blood Cells (RBCs), Plasma,
More informationLaboratory Empowerment. Debbie Asher Adrian Ebbs Transfusion Laboratory Managers, Eastern Pathology Alliance
Laboratory Empowerment Debbie Asher Adrian Ebbs Transfusion Laboratory Managers, Eastern Pathology Alliance Why? Electronic ICE requesting was in use for requesting red cells NBTC Indication Codes were
More informationMassive transfusion: Recent advances, guidelines & strategies. Dr.A.Surekha Devi Head, Dept. of Transfusion Medicine Global Hospital Hyderabad
Massive transfusion: Recent advances, guidelines & strategies Dr.A.Surekha Devi Head, Dept. of Transfusion Medicine Global Hospital Hyderabad Massive Hemorrhage Introduction Hemorrhage is a major cause
More informationA Compendium of Transfusion Practice Guidelines
A Compendium of Transfusion Practice Guidelines First Edition 2010 Authors: NurJehan Quraishy, MD (Chair), Western Lake Erie Region Gary Bachowski, MD, PhD, North Central Region Richard J. Benjamin, MD,
More informationTransplants. Mickey B. C. Koh
Transfusion in Stem Cell Transplants Mickey B. C. Koh Director: Stem Cell Transplant Programme Department of Haematology, St. George s Hospital and Medical School, London, UK Medical Director: Cell Therapy
More informationDisclosures. Committee on Blood and Blood Products) Co-investigator CBS Small Project. in Solid Organ Transplant Recipients
Neonatal Transfusion: Irradiation and CMV 6 th Annual Blood Matters Conference November 6 th, 2015 Disclosures Member of NAC (National Advisory Committee on Blood and Blood Products) Co-investigator CBS
More informationTransfusion Medicine Kris0ne Kra1s, M.D.
Transfusion Medicine Kris0ne Kra1s, M.D. Transfusion Medicine Outline Blood groups Introduc0on ABO system Rh system Other systems Blood transfusion Blood products Indica0ons Tes0ng Dangers Transfusion
More informationIn The Name Of GOD ADVERSE REACTIONS OF TRANSFUSION
In The Name Of GOD The 7 th international and 12 th national congress on quality improvement in clinical laboratories ADVERSE REACTIONS OF TRANSFUSION By Mehdi Allahbakhshian, PhD, Hematology and Blood
More informationBloodborne Pathogen CEU Training Course $ HOUR RUSH ORDER PROCESSING FEE ADDITIONAL $50.00
Registration form Bloodborne Pathogen CEU Training Course $100.00 48 HOUR RUSH ORDER PROCESSING FEE ADDITIONAL $50.00 Start and finish dates: You will have 90 days from this date in order to complete this
More informationThinking Twice About Transfusions: When TACOS and TRALIs Turn Treatment Into Tragedy. Megan Boysen Osborn, MD, MHPE
Thinking Twice About Transfusions: When TACOS and TRALIs Turn Treatment Into Tragedy Megan Boysen Osborn, MD, MHPE Let s TACO bout Transfusion Reactions Megan Boysen Osborn, MD, MHPE Let s TACO bout Transfusion
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Anemia(s), 412 426 categories in morphologic approach to, macrocytic, 412 414 microcytic, 412 414 normocytic, 412 413 categorizing, 412
More informationHematologic Disorders. Assistant professor of anesthesia
Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More information4100: Cellular Therapy Essential Data Follow-Up Form
4100: Cellular Therapy Essential Data Follow-Up Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: Visit: 100 day 6 months 1 year 2 years >2 years, Specify:
More informationIndex. Note: Page numbers of article numbers are in boldface type.
Index Note: Page numbers of article numbers are in boldface type. A Abdomen, acute, as cancer emergency, 381 399 in cancer patients, etiologies unique to, 390 392 in perforation, 388 surgery of, portal
More informationUnrestricted. Dr ppooransari fellowship of perenatalogy
Unrestricted Dr ppooransari fellowship of perenatalogy Assessment of severity of hemorrhage Significant drops in blood pressure are generally not manifested until substantial bleeding has occurred, and
More informationJuly 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
July 3, 2013 The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Physician Compare Intelligent Search To Whom it May Concern, The American
More information